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Abstract
Background: The HIV Dementia Scale (HDS) and International HIV Dementia Scale (IHDS) are brief tools that have been
developed to screen for and aid diagnosis of HIV-associated dementia (HAD). They are increasingly being used in clinical
practice for minor neurocognitive disorder (MND) as well as HAD, despite uncertainty about their accuracy.
Methods and Findings: A systematic review of the accuracy of the HDS and IHDS was conducted. Studies were assessed on
Standards for Reporting Diagnostic Accuracy criteria. Pooled sensitivity, specificity, likelihood ratios (LR) and diagnostic odds
ratios (DOR) were calculated for each scale as a test for HAD or MND. We retrieved 15 studies of the HDS, 10 of the IHDS, and
1 of both scales. Thirteen studies of the HDS were conducted in North America, and 7 of the IHDS studies were conducted in
sub-Saharan Africa. Estimates of accuracy were highly heterogeneous between studies for the HDS but less so for the IHDS.
Pooled DOR for the HDS was 7.52 (95% confidence interval 3.75–15.11), sensitivity and specificity for HAD were estimated at
68.1% and 77.9%, and sensitivity and specificity for MND were estimated at 42.0% and 91.2%. Pooled DOR for the IHDS was
3.49 (2.12–5.73), sensitivity and specificity for HAD were 74.3% and 54.7%, and sensitivity and specificity for MND were
64.3% and 66.0%.
Conclusion: Both scales were low in accuracy. The literature is limited by the lack of a gold standard, and variation in
estimates of accuracy is likely to be due to differences in reference standard. There is a lack of studies comparing both
scales, and they have been studied in different populations, but the IHDS may be less specific than the HDS. These rapid
tests are not recommended for diagnostic use, and further research is required to inform their use in asymptomatic
screening.
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Introduction
HIV-associated neurocognitive disorders (HAND) are defined
as impairment of multiple cognitive domains in association with
HIV, in the absence of other causes for the impairment [1].
HAND may affect up to half of all HIV positive (HIV+)
individuals, even in regions with good access to antiretroviral
therapy (ART) [2,3]. Symptomatic HAND (HIV-associated
dementia [HAD] or minor neurocognitive disorder [MND]) is
recommended as a reason to initiate [4,5] or modify [4] ART in
recent European and British clinical guidelines.
The ‘‘Frascati criteria’’ are a research classification system that
define HAD, the most severe grade of HAND, as impairment in at
least two cognitive domains, scoring at least 2 standard deviations
(SD) below demographically-appropriate means, with marked
impairment of activities of daily living (ADL) caused by the
cognitive deficits [1]. The two milder grades of HAND, much
more common than HAD, are MND (defined as at least 1 SD
below the mean in two domains with at least moderate
impairment of ADL) and asymptomatic neurocognitive impair-
ment (ANI) (defined similarly to MND but without impairment of
ADL).
Fulfilment of the Frascati criteria requires neuropsychological
(NP) testing of at least five cognitive domains from a possible
seven, assessment of ADL, and exclusion of other diagnoses. The
criteria are further limited by the lack of a standardised method of
grading ADL, uncertainty about the clinical significance and
possible oversensitivity for mild impairment [6], and lack of
confirmatory neuropathological, imaging or laboratory biomark-
ers. The 1991 American Academy of Neurology (AAN) criteria are
simpler to use, in that they only require that clinical diagnosis is
‘‘supplemented by’’ neuropsychological assessment, but are
otherwise very similar to the Frascati criteria [7]. The 1998
Memorial Sloan-Kettering (MSK) criteria are based largely on
clinical assessment and therefore may be more subjective, and are
suited to an era prior to the availability of ART when HAD was
terminally progressive [8].
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Given the complexity of diagnosis, there is a role for rapid tests
that can be incorporated into routine asymptomatic screening.
The HIV Dementia Scale (HDS) was developed in 1995 as a
‘‘brief but sensitive instrument to identify [HIV-associated]
dementia’’ [9]. The scale comprises four tests of subcortical
cognitive domains (attention, motor speed, construction, and
working memory). In response to culturally-specific elements of the
HDS and difficulties with the administration of the anti-saccadic
errors test, the International HIV Dementia Scale (IHDS) was
developed as an alternative in 2005 [10]. Both tests provide a score
but have a standardised cut-off for determining a positive or
negative result. Both were proposed as rapid tests for screening (i.e.
for individuals free of significant symptoms) and not diagnostic
tests to confirm disease in patients with signs or symptoms of
HAND, and patients who test positive with either the HDS or
IHDS should undergo further assessment for diagnosis [9,10].
Other brief clinical screening tools [2,11–19] and computerised
cognitive test batteries [20–22] have been used, but there are fewer
studies of their accuracy.
The HDS and IHDS have been used in recent clinical studies in
North and Central America [23,24], sub-Saharan Africa [12,25],
South Asia [26,27] and Europe [2,28,29], and have been
considered for inclusion as screening tools in expert HIV
treatment guidelines [19,30] (although the IHDS has recently
been replaced with a three-symptom questionnaire in updated
European guidelines [4]), but important questions remain. First,
they were devised for identifying HAD, and their performance in
detecting milder neurocognitive impairment may be quite
different. Second, it is unknown whether one scale has better
accuracy than the other. And third, the study methods, settings
and estimates vary considerably between diagnostic accuracy
studies. To enable evidence-based use of these tests in clinical
practice, we conducted a systematic review to estimate the
accuracy of each scale for the diagnosis of HAD and MND when
compared to standard diagnostic criteria.
Methods
Search strategy and selection criteria
A literature search was conducted in July 2011 and repeated in
January 2013 by the first author, including PubMed and PsycInfo
indexes, searchable online HIV/AIDS conference proceedings,
specialist journals, and major online sources of HIV-related
information. Search terms were formulated to capture all studies
using the HDS or IHDS alongside another diagnostic method for
HAND in a sample of HIV positive adults (Table 1). Manual
searches included reference lists of relevant articles identified in
automated searches, conference proceedings, and requests for
unpublished data to authors of major articles. PubMed and
PsycInfo searches were limited to 1994 onwards (the year prior to
publication of the HDS) and conference abstracts were limited to
available years (mainly 2001 onwards).
From this initial search, studies were excluded if they duplicated
data reported in another study in the search, and were only
included if they used either the HDS or IHDS to assess individual
HIV+ adults, as well as an appropriate reference standard for
comparison. In this review, the highest-quality reference standard
was a standardised clinical definition (Frascati, AAN, or MSK)
supported by a NP battery evaluating at least five broad cognitive
domains (attention and working memory; verbal and/or visual
learning and recall; processing speed; executive functions; motor
skills). Studies using other reference standards such as a detailed
NP battery only, clinical opinion or brief NP tools were reviewed
but not included in all stages of the analysis (see below).
Assessment of study quality
Data collected for each study included study identifiers, the
year(s) in which the work was conducted, geographical region,
details of HIV positive study participants (number, age, education,
degree of immunodeficiency, ART coverage, drug and alcohol
use, psychiatric conditions, and relevant co-morbidities), test of
interest (HDS or IHDS), reference standard for comparison,
possible sources of bias and error, and the results of the test of
interest and reference standard. Authors of papers with useable
data were contacted to clarify their methodology.
Possible sources of bias and error were identified from a pre-
specified list of quality criteria, based on Standards for Reporting
Diagnostic Accuracy (STARD) guidelines [31]. Criteria to assess
selection methods were the target population, inclusion and
exclusion criteria, sampling methodology (consecutive, random, or
opportunistic), information about eligible patients who were not
recruited, and whether there was an a priori power calculation.
Criteria relating to diagnostic methods included whether assessors
completing the test and the reference standard were blinded to
each other’s assessment, adequacy and appropriateness of methods
used for the reference standard, methods of ensuring validity and
reliability of the assessments, and time lag or drop-outs between
assessments. Studies were also assessed on whether the patient
sample was adequately described, and whether there were any
characteristics of the sample that might reduce its generalizability.
Collection of screening or diagnostic accuracy data
The number of true and false positives (TP, FP) and number of
true and false negatives (TN, FN) among HIV+ study subjects,
using standard cut-offs for the test of interest (less than or equal to
10 for both scales), was determined. The reference standard was
categorised as having either a severe or a moderate threshold.
Severe threshold reference standards were those using Frascati or
AAN criteria for HAD, or the MSK grading for AIDS Dementia
Complex (grade 1 to 4). All three of these standards are similar in
threshold, although the Frascati definition for HAD may represent
the more severe end of the impairment spectrum [32]. Severe
impairment in studies employing NP batteries was defined by
similar criteria to HAD, namely impairment to $2 SD below
normative means in at least two out of five cognitive domains.
Moderate threshold reference standards were those that used
MND (Frascati criteria), Minor Cognitive-Motor Disorder
(MCMD; AAN criteria), or MSK grade 0.5 as a cut-off, with
more severe impairment also included as a positive diagnosis.
There is slightly less agreement between MND, MCMD, and
MSK grade 0.5 than for more severe impairment [32,33].
Moderate impairment in studies using NP batteries was defined
by similar criteria to MND, namely impairment in at least two
domains at a level of at least 1 SD below expected means.
If the necessary values could not be extracted from published
papers, but it was apparent that the necessary source data might
exist elsewhere (e.g. if test scores were reported as a continuous
distribution), the corresponding author was contacted to request
these data. If it was not possible to dichotomise both the test of
interest and the reference standard, the study was excluded from
the analysis.
The accuracy of the test of interest in each study was quantified
by the sensitivity (true positive rate), specificity (1–false positive
rate), positive likelihood ratio (LR+; equal to sensitivity 4
[12specificity]), negative likelihood ratio (LR2; equal to [12sen-
sitivity] 4 specificity), and diagnostic odds ratio (DOR; equal to
[TP6TN] 4 [FP6FN]). Positive and negative LR can be
multiplied by the assumed odds of a diagnosis being present
before conducting the test (prior odds) to determine the final odds
Systematic Review of HIV Dementia Scales
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of a diagnosis being present (posterior odds). According to
Jaeschke et al, tests with LR+ .5 or LR2 ,0.2 provide strong
evidence for or against the diagnosis, and LR+ .10 and LR2
,0.1 provide convincing diagnostic evidence in most scenarios
[34]. 95% confidence intervals (CI) were calculated for each
measure.
Statistical analysis
Four groups of studies were defined, according to the test of
interest (separate analyses were performed for the HDS and
IHDS) and the reference standard threshold (severe or moderate).
Some studies reported more than one grade of impairment and
therefore contributed to more than one group. Studies were then
pooled if they used comprehensive criteria (Frascati, AAN or
MSK), but were discounted if they used only a NP battery or a
brief tool as the reference standard. Studies were not excluded on
the basis of other quality criteria. Where there were two reference
standards applied to the same sample, the more comprehensive
standard was retained.
For each of these four pools of studies, heterogeneity between
estimates of sensitivity and specificity was assessed by chi-squared
tests, ignoring studies with cell sizes of ,5. Heterogeneity between
estimates of LRs was assessed using the I-squared measure.
Reasons for heterogeneity between studies were later assessed by
meta-regression of LRs with study characteristics as the indepen-
dent variable.
Pooled sensitivity and specificity were then calculated as
averages, weighted by sample size, and pooled LR+ and LR2
were calculated using standard meta-analysis methods for risk
ratios with a random effects model. These methods have the
potential to underestimate test accuracy in the presence of
diagnostic threshold variation; such variation was assessed using
Spearman’s rank test to demonstrate correlation between sensi-
tivity and specificity [35]. A summary DOR that is constant across
diagnostic threshold removes this source of error [36].
Summary DORs were calculated using the Littenberg-Moses
method [37] in which the linear relationship D= a+bS is examined
in a regression model (where D = exp(DOR) and S = logit[TPR]
+ logit[FPR]), with points weighted by the square root of sample
size. When calculating DORs, it was possible to combine studies
with severe and moderate reference thresholds, and those with
detailed NP batteries as the reference standard were re-incorpo-
rated into the analysis. A continuity correction was applied,
because some studies had FN or FP equal to zero.
DORs are a single composite measure of both true- and false-
positive rates, and therefore less clinically useful than other
measures. To assist interpretation, predicted specificity and LRs
were calculated from the average sensitivity and the summary
DOR.
Results
Studies included in the review (Figure 1; Flowchart S1)
The literature search generated 3698 unique citations, of which
56 reported using the HDS or IHDS and a reference standard in
the same HIV positive sample. Of these, 28 were discarded
because they did not dichotomise both test results
[17,21,26,28,38–61], and one was excluded because it used a
non-standard cut-off [62]. A further study in rural Zambia was
excluded because it was observed that all 48 HIV positive
participants and all 15 HIV-negative controls scored positively
(impaired) on the HDS [12]. The remainder comprised 15 studies
of the HDS [2,9,23,24,63–73], ten of the IHDS [10,25,74–81],
and one of both the HDS and IHDS [13]. One of the IHDS
studies reported results from two populations and was considered
as two separate studies in all further analyses [10].
Of the 27 studies meeting inclusion criteria (Table 2), several
sampled high risk target populations, including patients in the pre-
highly active ART (HAART) era [9], admissions to specialist
AIDS facilities [64,79], patients with low CD4+ counts [10,78,79],
patients in regions with limited access to ART [10,24,25,74–
76,78,79], and individuals with psychiatric illness or drug abuse
[71]. Nearly all studies recruited patients unselected for neuro-
cognitive symptoms, apart from four studies that specifically
targeted those with cognitive complaints [10,76,77] or neurology
clinic referrals [13]. In contrast, two studies targeted virologically
stable patients [2,63], and two studies excluded patients known to
have significant dementia [72,75]. Eighteen studies excluded
patients with confounding conditions, mainly neurological disor-
ders (n=14 studies) [2,9,10,23–25,63,64,66,70,76,78,80], psychi-
atric conditions (n=11) [2,10,23–25,66,72,76,78,80], systemic
illnesses (n=10) [2,9,10,24,63,66,76,79], and drug or alcohol use
(n=8) [9,23,25,63,66,72,78]. Thirteen of the HDS studies were
conducted in USA or Canada, with one HDS study in each of
South Africa, Switzerland, and Puerto Rico. In contrast, only
three of the IHDS studies were conducted in North America, one
in India, and one in Italy, with the remainder from sub-Saharan
Africa. Characteristics of the patients in HDS studies (n = 3143)
and IHDS studies (n = 942) are shown in Table 3.
Methodology and study quality
Methodological characteristics relating to study quality are
summarised in Figure 2. Eighteen studies were specifically
designed to assess one of the screening tools [2,9,10,13,23–
25,64–66,68,71–75,78,79,81]. The sampling method was random
or consecutive in only seven samples (allowing for some ambiguity
in reporting) [2,23,68,72,75,79,80]. The number of eligible
patients who were not recruited was available for seven studies.
No published articles reported any justification for their sample
Table 1. Search terms.
‘‘HIV’’ OR ‘‘HIV infections [MeSH]’’ OR ‘‘Acquired Immunodeficiency Syndrome [MeSH]’’ OR ‘‘AIDS Dementia Complex [MeSH]’’
AND
‘‘AIDS Dementia Complex [MeSH]’’ OR ‘‘dementia’’ OR ‘‘cogniti*’’ OR ‘‘neurocognitive’’ OR ‘‘neuropsych*’’ OR ‘‘encephalopath*’’ OR ‘‘encephaliti*’’ OR ‘‘dementia [MeSH]’’
OR ‘‘executive function [MeSH]’’ OR ‘‘cognition [MeSH]’’
AND
‘‘diagnos*’’ OR ‘‘sensitiv*’’ OR ‘‘specific*’’ OR ‘‘accura*’’ OR ‘‘scale’’ OR ‘‘score’’ OR ‘‘predictive value’’ OR ‘‘likelihood ratio’’ OR ‘‘sensitivity and specificity [MeSH]’’ OR ‘‘ROC
curve [MeSH]’’ OR ‘‘predictive value of tests [MeSH]’’ OR ‘‘diagnosis [MeSH]’’ OR ‘‘neuropsychological tests [MeSH]’’ OR ‘‘intelligence tests [MeSH]’’
These search terms were for PubMed, the primary source of citations. Searches of other data sources used modified versions of these terms.
doi:10.1371/journal.pone.0061826.t001
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size, but one author disclosed that they had performed a power
calculation [75].
Two studies used inadequate reference standards: the Mini
Mental State Examination [68], or a short NP battery only [79].
Five studies used standard definitions based on clinical assessment
but either did not report their NP battery [9,64,80] or used a
battery assessing fewer than five domains [13,79], and six studies
used a NP battery only [66,70–73,81]. Norms were generally
based on published demographically-standardised data, but two
studies collected normative data from local HIV-negative samples
[24,25], and six studies based in Africa used norms primarily
derived from US populations [10,74–76,78,79]. Methods for
quality control of the HDS or IHDS included test-retest methods
[9], specialist supervision and training [25,71,73–75,78,79],
improved standardisation [25,71,72], and expert panel review
was used for the reference standard in some studies [10,74–76].
Full [24,69,78,79] or partial [23,74,75] blinding between
assessments occurred in seven studies, and most studies did not
Figure 1. Systematic review flowchart. Footnote: * Of the final 26 studies in the review, one comprised two separate populations [10], which are
treated as two different studies in all further analyses.
doi:10.1371/journal.pone.0061826.g001
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report the use or non-use of blinding. Lack of blinding was usually
due to assessments being done by the same investigator.
Verification bias was difficult to exclude with available informa-
tion, but three studies had a time-lag between assessments
[9,23,64].
Estimates of accuracy of the HIV Dementia Scale
Sensitivity estimates for detecting severe HAND with the HDS
ranged widely from 35.7–91.7%, specificity 60.4–100%, LR+
1.89–6.29, and LR2 0.12–0.72 (Table 4). After removing studies
with NP batteries or brief tools as reference standards, there was
evidence of heterogeneity between these estimates (p = 0.10 for
LR+; p = 0.06 for LR2; p = 0.03 for sensitivity; p,0.001 for
specificity). There was borderline evidence of a correlation
between sensitivity and specificity across these studies (Spearman’s
r=20.68 for nine observations, p = 0.062). Pooling seven studies
that used a comprehensive reference standard gave sensitivity
68.1% (95% CI 59.2–75.9%), specificity 80.2% (76.6–83.5%),
LR+ 3.76 (2.65–5.33), LR2 0.42 (0.29–0.63).
Sensitivity estimates for detecting moderate-to-severe HAND
were again in a wide range from 9.1–61.5%, specificity 62.5–
97.8%, LR+ 1.33–7.00, LR2 0.47 to 0.93. There was also
Table 2. Methods of assessment, target population, and exclusion criteria in studies of the HIV Dementia Scale (HDS) and
International HIV Dementia Scale (IHDS).
Citation Reference assessment method* Country Target patient population Major exclusion criteria**
Test of interest: HIV Dementia Scale
Avison [63] MSK grading and NP battery USA Stable for 3 months A, C, E
Berghuis [64] Previous clinical diagnosis, based on
AAN criteria
USA Hospitals & community AIDS
care facilities
C
Bottiggi [65] MSK grading and NP battery USA On or due to receive ART A, C, E
Carey [66] NP battery USA Patients enrolled in research projects A, C, D, E
Cloak [67] MSK grading USA Unspecified HIV population B, C, D, E
Ganasen [68] Mini Mental State Examination South Africa Primary healthcare HIV clinics NR
Gongvatana [69] AAN criteria USA Unspecified HIV population A, B, C, D
Hardy [70] NP battery USA Infectious disease clinic B, C
Morgan [23] AAN criteria (previously applied)*** USA Pts enrolled in research projects A, B, C, D
Power [9] AAN criteria (clinical assessment only) USA Pre-HAART era A, C, E
Richardson [71] NP battery USA Psychiatric illness or substance abuse None
Sakamoto [73] NP battery USA Broad cohort, 6 research clinic sites None
Simioni [2] Frascati criteria Switzerland Undetectable viral load, on ART C, D
Smith [72] NP battery USA Cognitively asymptomatic;
unemployed
A, D
Wojna [24] AAN criteria Puerto Rico Women B, C, D
Test of interest: International HIV Dementia Scale
Antinori [81] Frascati criteria Italy On HAART, otherwise unspecified NR
Joska [25] Frascati criteria South Africa Primary healthcare HIV clinics A, B, C, D
Kwasa [74] MSK grading and Frascati criteria Kenya Rural Kenya None
Meyer [75] MSK grading and Frascati criteria Kenya Rural Kenya None
Muniyandi [80] MSK grading (clinical assessment only) India Medical college hospital ART clinic C, D, E
Nakasujja [76] MSK grading Uganda Off ART at baseline; pts with NCI C, D, E
Sacktor [77] MSK grading USA Progressive NCI; enrolled in a
treatment trial; stable HAART
A, C, D
Sacktor [10]**** MSK grading Uganda US-sponsored infectious diseases
clinic
C, D, E
Sacktor [10]**** MSK grading USA CD4,200, or CD4,300 with NCI C, D, E
Singh [79] Brief NP battery South Africa Ward admissions; low CD4 F
Singh [78] Frascati criteria (using a brief NP battery) South Africa HIV outpatients; CD4 200–350 A, B, C, D
Tests of interest: HDS and IHDS
Skinner [13] AAN criteria (using a brief NP battery) Canada Neurology clinic referrals None
*Unless stated, assessment for comprehensive clinical criteria (MSK, AAN, or Frascati) included neuropsychological evaluation of at least 5 cognitive domains.
**Major exclusion criteria were: A, past and/or recent drug and/or alcohol abuse; B, head trauma with loss of consciousness; C, neurological illness; D, psychiatric illness;
E, systemic illness that may affect CNS function.
***Participants were randomly selected from an existing cohort, in proportions approximating published prevalence of MND and HAD.
****The paper reported two independent samples, treated as separate studies in this review.
AAN: American Academy of Neurology; ART: antiretroviral therapy; HAART: highly active antiretroviral therapy; HDS: HIV dementia scale; IHDS: international HIV
dementia scale; MSK: Memorial Sloan-Kettering; NCI: neurocognitive impairment; NP: neuropsychological; NR: not reported.
doi:10.1371/journal.pone.0061826.t002
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heterogeneity between estimates (p = 0.03 for sensitivity; p,0.001
for specificity; p = 0.03 for LR+), although not for LR2 (p = 0.28),
but little evidence of correlation between sensitivity and specificity
in this pool of studies (r=20.77 for six observations, p = 0.07).
Pooled estimates were sensitivity 42.0% (34.6–49.7%), specificity
83.3% (78.4–87.3%), LR+ 3.18 (1.70–5.95), LR2 0.70 (0.60–
0.81).
The summary DOR for the HDS was estimated at 7.52 (3.75–
15.11) (Figure 3). Predictions of test accuracy for the HDS were
made using the above pooled sensitivity estimates (68.1% and
42.0%), giving specificity of 77.9% for severe HAND and 91.2%
for moderate-to-severe HAND, LR+ of 3.08 and 4.79, and LR2
of 0.41 and 0.64, respectively. Repeat analysis using only studies
with the highest-quality reference standards and populations
unselected for neurocognitive symptoms gave slightly poorer
Figure 2. Methodology and reporting of reviewed studies: A, the HIV Dementia Scale; B, International HIV Dementia Scale. Olive-
green bars indicate fulfilment of study quality criteria, red bars indicate non-fulfilment, and blue bars indicate that this feature was not reported or
available from correspondence with the study author. The study by Skinner et al [13] applied both scales to the same patient sample and is
represented in both graphs A and B. HAND: HIV-associated neurocognitive disorder.
doi:10.1371/journal.pone.0061826.g002
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Table 4. Estimates of diagnostic accuracy reported in studies in the review.
Citation Reference standard*
% Sensitivity
(95% CI)
% Specificity
(95% CI)
Positive likelihood
ratio (95% CI)
Negative likelihood
ratio (95% CI)
Test of interest: HIV Dementia Scale, Reference standard threshold: Severe neurocognitive impairment
Avison [63] MSK criteria 75.0 (30.1–95.4) 85.0 (64.0–94.8) 5.00 (1.53–16.38) 0.29 (0.05–1.62)
NP battery 60.0 (23.1–88.2) 84.2 (62.4–94.5) 3.80 (1.08–13.41) 0.48 (0.16–1.41)
Berghuis [64] AAN criteria, by retrospective clinical
assessment
91.7 (64.6–98.5) 71.4 (61.4–79.7) 3.21 (2.22–4.63) 0.12 (0.02–0.77)
Bottiggi [65] NP battery 71.4 (35.9–91.8) 76.9 (61.7–87.4) 3.10 (1.48–6.49) 0.37 (0.11–1.21)
Cloak [67] MSK criteria 60.0 (23.1–88.2) 100 (50.9–100) 5.83 (0.39–88.12) 0.46 (0.17–1.25)
Ganasen [68] Mini Mental State Examination 81.8 (52.3–94.9) 79.9 (76.0–83.3) 4.07 (2.92–5.68) 0.23 (0.07–0.80)
Gongvatana [69] AAN criteria 53.3 (30.1–75.2) 90.9 (78.8–96.4) 5.87 (2.06–16.72) 0.51 (0.30–0.89)
Morgan [23] AAN criteria 35.7 (16.3–61.2) 91.7 (85.5–95.4) 4.32 (1.72–10.84) 0.70 (0.47–1.04)
Power [9] AAN criteria (clinical assessment only) 76.1 (62.1–86.1) 87.9 (79.6–93.1) 6.29 (3.53–11.21) 0.27 (0.16–0.46)
Richardson [71] NP battery 55.0 (34.2–74.2) 75.0 (53.1–88.8) 2.20 (0.93–5.18) 0.60 (0.35–1.04)
Simioni [2] Frascati criteria 75.0 (30.1–95.4) 60.4 (50.4–69.6) 1.90 (1.02–3.51) 0.41 (0.08–2.28)
Smith [72] NP battery 38.6 (25.7–53.4) 84.8 (71.8–92.4) 2.54 (1.17–5.52) 0.72 (0.56–0.94)
Wojna [24] AAN criteria 68.8 (44.4–85.8) 79.5 (65.5–88.8) 3.36 (2.65–5.33) 0.39 (0.19–0.83)
Test of interest: HIV Dementia Scale, Reference standard threshold: Moderate-to-severe neurocognitive impairment
Avison [63] NP battery 50.0 (23.7–76.3) 92.9 (68.5–98.7) 7.00 (0.96–51.09) 0.54 (0.29–1.02)
Bottiggi [65] MSK criteria 47.8 (29.2–67.0) 90.1 (72.2–97.5) 5.26 (1.31–21.09) 0.57 (0.38–0.87)
Carey [66] NP battery 9.1 (3.9–19.6) 97.8 (93.7–99.2) 4.09 (1.01–16.53) 0.93 (0.85–1.02)
Gongvatana [69] AAN criteria 28.2 (16.5–43.8) 95.0 (76.4–99.1) 5.64 (0.78–40.65) 0.76 (0.61–0.94)
Hardy [70] NP battery 40.9 (23.3–61.3) 90.5 (77.9–96.2) 4.30 (1.49–12.38) 0.65 (0.46–0.94)
Morgan [23] AAN criteria 27.8 (15.8–44.0) 94.9 (88.7–97.8) 5.50 (2.02–15.00) 0.76 (0.62–0.94)
Sakamoto [73] NP battery 24.4 (21.5–27.4) 91.6 (89.4–93.3) 2.89 (2.22–3.76) 0.83 (0.79–0.86)
Simioni [2] Frascati criteria 50.0 (32.6–67.4) 62.5 (51.0–72.8) 1.33 (0.83–2.15) 0.80 (0.53–1.21)
Skinner [13] AAN criteria (using brief NP battery) 61.5 (35.5–82.3) 80.0 (58.4–91.9) 3.08 (1.16–8.17) 0.48 (0.23–0.99)
Wojna [24] AAN criteria 60.9 (40.8–77.8) 83.8 (68.9–92.3) 3.75 (1.68–8.37) 0.47 (0.28–0.79)
Test of interest: HIV Dementia Scale, Reference standard threshold: Any grade of neurocognitive impairment
Simioni [2] Frascati criteria** 54.1 (42.8–64.9) 96.2 (81.1–99.3) 14.05 (2.03–97.15) 0.48 (0.37–0.62)
Test of interest: International HIV Dementia Scale, Reference standard threshold: Severe neurocognitive impairment
Joska [25] Frascati criteria 57.1 (40.9–72.0) 65.6 (53.0–76.3) 1.66 (1.06–2.60) 0.65 (0.43–1.00)
Kwasa [74] MSK criteria 100 (56.4–100) 48.0 (30.0–66.5) 1.77 (1.14–2.75) 0.17 (0.01–2.54)
Meyer [75] MSK criteria 78.9 (56.7–91.5) 44.5 (38.1–51.1) 1.42 (1.10–1.85) 0.47 (0.20–1.14)
Frascati criteria 100 (34.2–100) 43.0 (36.8–49.4) 1.46 (0.87–2.46) 0.39 (0.03–4.89)
Muniyandi [80] MSK criteria (clinical assessment only) 100 (43.8–100) 40.0 (24.6–57.7) 1.67 (1.24–2.23) 0.31 (0.02–4.29)
Nakasujja [76] MSK criteria 100 (20.6–100) 23.6 (15.3–34.6) 0.99 (0.44–2.22) 1.04 (0.09–11.91)
Sacktor [77]
(Minocycline study)
MSK criteria 75.0 (60.6–85.4) 44.8 (32.7–57.5) 1.36 (1.02–1.81) 0.56 (0.31–1.00)
Sacktor [10] (US-based
cohort)***
MSK criteria 80.0 (60.9–91.1) 55.4 (42.4–67.6) 1.79 (1.26–2.55) 0.36 (0.16–0.82)
Sacktor [10] (Ugandan
cohort)***
MSK criteria 80.0 (60.9–91.1) 56.1 (41.0–70.1) 1.82 (1.22–2.71) 0.36 (0.16–0.82)
Singh [79] (inpatient
cohort)
Brief NP battery 81.8 (52.3–94.9) 22.2 (6.3–54.7) 1.05 (0.67–1.64) 0.82 (0.14–4.71)
Singh [78] (outpatient
cohort)
Frascati criteria (using brief NP battery) 70.0 (39.7–89.2) 65.0 (52.4–75.8) 2.00 (1.17–3.41) 0.46 (0.18–1.21)
Test of interest: International HIV Dementia Scale, Reference standard threshold: Moderate-to-severe neurocognitive impairment
Joska [25] Frascati criteria 53.8 (41.9–65.4) 80.6 (63.7–90.8) 2.78 (1.31–5.91) 0.57 (0.42–0.78)
Kwasa [74] Frascati criteria 77.8 (45.3–93.7) 47.6 (28.3–67.6) 1.49 (0.87–2.54) 0.47 (0.13–1.72)
Meyer [75] Frascati criteria 71.8 (56.2–83.5) 45.5 (38.7–52.4) 1.32 (1.04–1.66) 0.62 (0.37–1.05)
Singh [79] (inpatient
cohort)
Brief NP battery 87.5 (64.0–96.5) 50.0 (15.0–85.0) 1.75 (0.65–4.74) 0.25 (0.05–1.27)
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accuracy estimates as follows: DOR 5.25 (1.42–19.44); sensitivity
55.6%, specificity 80.8%, LR+ 2.89, LR2 0.55 (severe HAND);
sensitivity 38.0%, specificity 89.5%, LR+ 3.64, LR2 0.69
(moderate-to-severe HAND).
Estimates of accuracy of the International HIV Dementia
Scale
For the IHDS, sensitivity estimates for detecting severe HAND
ranged from 57.1–100%, specificity 22.2–65.6%, LR+ 1.05–2.00,
and LR2 0.31–0.82 (Table 4). Two sets of estimates came from
the same study, one using MSK grading and one using Frascati
criteria [75]; the latter was dropped from further analysis because
the researchers found limitations to using Frascati criteria in rural
Kenya. There was strong evidence of heterogeneity between
studies in the specificity estimates (p,0.001), and correlation
between sensitivity and specificity across IHDS studies using a
valid reference standard (r=20.69 for nine observations,
p = 0.04), but little evidence of heterogeneity of sensitivity and
LR estimates (p.0.10). Pooling studies using gave sensitivity
74.3% (67.1–80.3%), specificity 47.8% (43.9–51.8%), LR+ 1.56
(1.36–1.79), LR2 0.52 (0.40–0.68).
Sensitivity estimates for detecting moderate-to-severe HAND
with the IHDS ranged from 53.8–87.5%, with specificity 45.0–
80.6%, LR+ 1.32–2.78, LR2 0.25–0.62, with one conspicuous
outlier of low sensitivity and high specificity [25]. There was strong
evidence of heterogeneity between specificity estimates (p = 0.004),
borderline evidence of heterogeneity between sensitivity estimates
(p = 0.07), and no evidence of heterogeneity between LR estimates
(p.0.10). There was no evidence of a correlation between
sensitivity and specificity (r=20.80 for four observations,
p = 0.20). Pooled estimates were sensitivity 64.3% (55.6–72.1%),
Figure 3. Receiver-operator characteristic curve calculated from summary diagnostic odds ratio for the HIV Dementia Scale. Blue
checks indicate sensitivity and specificity estimates from individual studies using comprehensive reference standards, labelled by first author. Red
circles indicate studies using neuropsychological (NP) test batteries or brief NP tests as the reference standard, again labelled by first author. Solid
diamonds indicate predicted values based on pooled sensitivity and summary diagnostic odds ratio. A, Reference standard = AIDS dementia
complex, HIV-associated dementia, or severe impairment on NP battery. B, Reference standard = mild neurocognitive disorder, minor cognitive/
motor disorder, or moderate impairment on NP battery. CI: confidence interval; DOR: diagnostic odds ratio.
doi:10.1371/journal.pone.0061826.g003
Table 4. Cont.
Citation Reference standard*
% Sensitivity
(95% CI)
% Specificity
(95% CI)
Positive likelihood
ratio (95% CI)
Negative likelihood
ratio (95% CI)
Skinner [13] AAN criteria (using brief NP battery) 84.6 (57.8–95.7) 45.0 (25.8–65.8) 1.54 (0.97–2.44) 0.34 (0.09–1.34)
Test of interest: HIV Dementia Scale, Reference standard threshold: Any grade of neurocognitive impairment
Antinori [81] Frascati criteria** 55.0 (39.8–69.3) 82.0 (70.5–89.6) 3.05 (1.67–5.58) 0.55 (0.38–0.79)
*Unless stated, assessment for comprehensive clinical criteria (MSK, AAN, or Frascati) included neuropsychological evaluation of at least 5 cognitive domains.
**Studies using ANI as the reference standard are not included in summary estimates or figures.
***The paper reported two independent samples, treated as separate studies.
ADC: AIDS dementia complex; ANI: asymptomatic neurocognitive impairment; CI: confidence interval; HAD: HIV-associated dementia; HAND: HIV-associated
neurocognitive disorder; MCMD: minor cognitive/motor disorder; MMSE: mini mental state examination; MND: minor neurocognitive disorder; MSK: Memorial Sloan-
Kettering; NCI: neurocognitive impairment; NP: neuropsychological.
doi:10.1371/journal.pone.0061826.t004
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specificity 49.6% (43.7–55.6%), LR+ 1.73 (1.17–2.55), LR2 0.55
(0.41–0.74).
In summary, there was evidence of heterogeneity in specificity
among IHDS studies, with considerable overlap between the
ranges of estimates for detecting severe HAND and those for
detecting moderate HAND. A summary ROC curve was fitted
with a pooled DOR of 3.49 (2.12–5.73) (Figure 4). Predictions for
the IHDS were again made using pooled sensitivity estimates
(74.3% and 64.3%), giving specificity of 54.7% for severe HAND
and 66.0% for moderate-to-severe HAND, LR+ of 1.64 and 1.89,
and LR2 of 0.47 and 0.54, respectively. Repeat analysis using
only studies with high-quality reference standards and populations
unselected for neurocognitive symptoms gave similar results: DOR
3.54 (2.07–6.05); sensitivity 73.4%, specificity 56.2%, LR+ 1.68,
LR2 0.47 (severe HAND); sensitivity 61.9%, specificity 68.5%,
LR+ 1.97, LR2 0.56 (moderate-to-severe HAND).
Analysis of sources of heterogeneity
Analysis of study methodological features showed higher
average DOR (20.5 vs. 6.85, p = 0.001) and lower average LR2
(0.26 vs. 0.59, p= 0.01) in two studies comparing the HDS to a
severe-impairment reference standard when the target population
was highly immunodeficient [9,64]. When compared to the IHDS,
the HDS had a significantly higher summary DOR (p=0.009) and
LR+ (p = 0.019), but both scales had similar LR2 (p = 0.98). This
comparison may however be based on an artificial foundation,
given the differences between target populations in studies of each
scale. The single study that used both scales in the same
population was of small sample size and failed to find a difference
between the two [13].
Discussion
We have systematically reviewed 15 studies of the HDS, ten of
the IHDS, and one that included both scales. Most studies in the
review apply to the original intended role of the HDS and IHDS–
screening rather than diagnosis–in that participants were not
selected on the basis of symptoms. Summary estimates for the
HDS as a test for HAD or an equivalent diagnosis (severe HAND)
were: sensitivity 68%, specificity 78%, LR+ 3.1, LR2 0.41, but its
accuracy appeared to be lower when analysis was limited to studies
with high-quality reference standards and unselected populations.
When using the HDS as a test for MND or equivalent (all
symptomatic HAND), estimates of accuracy were: sensitivity 42%,
specificity 91%, LR+ 4.8, LR2 0.64. Summary estimates for the
IHDS as a test for severe HAND were: sensitivity 74%, specificity
55%, LR+ 1.6, LR2 0.47. When using the IHDS as a test for all
symptomatic HAND, estimates of accuracy were: sensitivity 64%,
specificity 66%, LR+ 1.9, LR2 0.54. These summary estimates
and most individual study estimates for both scales failed to
achieve accepted levels of accuracy to provide strong evidence for
a diagnosis of HAND [34], confirming their unsuitability for
diagnostic purposes when used alone.
Comparing the two scales, the HDS had a higher DOR and
LR+ than the IHDS, but the only direct comparison of both scales
within the same sample failed to find a difference between the two,
and was limited by its small sample size [13]. Furthermore, the two
scales were studied in different settings, with most of the HDS
studies conducted in North America, and most of the IHDS
studies conducted in Africa. Unfortunately, while the IHDS was
developed with resource-limited settings in mind, it is not free from
Figure 4. Receiver-operator characteristic curve calculated from summary diagnostic odds ratio for the International HIV Dementia
Scale. Blue checks indicate sensitivity and specificity estimates from individual studies, labelled by first author. Crosses labelled ‘‘Sacktor Uganda’’
and ‘‘Sacktor US’’ correspond to two separate studies published in a single paper [10]. The cross labelled ‘‘Sacktor MCN’’ corresponds to baseline data
from a multicentre trial of minocycline for treatment of cognitive impairment [77]. The two points labelled ‘‘Meyer’’ are derived from the same study
[75]; ‘‘(Frascati)’’ and ‘‘(MSK)’’ denote the reference standard in each case. Red circles indicate studies using neuropsychological (NP) test batteries or
brief NP tests as the reference standard, again labelled by first author. Solid diamonds indicate predicted values based on pooled sensitivity and
summary diagnostic odds ratio. A, Reference standard = AIDS dementia complex, HIV-associated dementia, or severe neurocognitive impairment. B,
Reference standard = mild neurocognitive disorder, minor cognitive/motor disorder, or mild/moderate neurocognitive impairment. CI: confidence
interval; DOR: diagnostic odds ratio.
doi:10.1371/journal.pone.0061826.g004
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culturo-linguistic effects. The four-word recall task (in both tests)
must be modified for different languages [24,52], and it was shown
in an Indian population that education was associated with IHDS
score, but HIV status was not [27]. The two scales were also
studied in different years, and considerable changes in our
understanding of HIV pathogenesis and treatment occurred in
the decade between the publication of the HDS in 1995 and the
IHDS in 2005.
Estimates of screening accuracy showed wide variation between
studies, particularly for the HDS. We did not find strong evidence
of a diagnostic threshold effect. However, tests of correlation used
to demonstrate this effect are known to have low statistical power
[36], and the reference diagnosis of HAD is complex and subject
to variations of interpretation. It is therefore plausible that
differences between reference standards contributed to the varying
accuracy of these well-standardised diagnostic tools.
Regarding other sources of variability, an increased DOR and
lower LR2 was seen in two studies assessing the HDS in patients
with more advanced immunodeficiency. Spectrum bias is a form
of selection bias that may occur when the study population is
sampled from a limited or specialised clinical setting and therefore
has a narrow spectrum of disease. This form of bias could have
increased sensitivity in samples of more severely-impaired patients,
such as those conducted in Africa, in the pre-HAART era, or in
hospital wards. Spectrum bias could also reduce specificity in those
in whom it was difficult to exclude competing diagnoses, such as in
resource-limited settings, or conversely increase specificity in
samples with fewer competing diagnoses. Non-random, non-
consecutive sampling strategies are known to lead to over-
estimation of accuracy [82].
There were a number of methodological limitations to this
review. First, the literature search and data extraction were carried
out by a single author (LJH). Second, the literature search could
have missed studies not cited in the target data sources, or articles
in which it was not clear from the abstract that neurocognitive
testing was done. To minimise this, researchers in the field were
asked about the existence of unpublished datasets. Third, it was
not always possible to generate two-by-two tables from available
data, usually because HDS and IHDS scores were reported as
continuous variables. In a few studies, the estimated values were
not consistent with other information in the same article,
suggesting other unknown errors in the results. This was despite
requests for reconfigured data directly from researchers.
More importantly, the review is limited by the lack of a clinical
gold standard for neurocognitive impairment in HIV, whether this
be neurological criteria, neuroimaging findings, biomarkers in
cerebrospinal fluid, or histopathology. The Frascati criteria are
relatively detailed, objective, and appropriate for a research
definition, so the analysis in this review provides the best available
estimates of the accuracy of the HDS and IHDS when used as
screening tools for MND or HAD. However, current data do not
clearly inform clinicians of the natural history or appropriate
treatment of these conditions, particularly milder impairment, and
this limits our ability to predict the effects of screening.
British HIV Association (BHIVA) guidelines do not comment
on screening for HAND [5], whereas the European AIDS Clinical
Society (EACS) guidelines recommend a brief symptom question-
naire in all patients at regular intervals [2,4] and a recent review
made similar recommendations but did not support one screening
test over another [83]. The general rule that one should minimise
false positives if the confirmatory test is expensive or invasive
favours the HDS over the IHDS, and the penalty for missing an
asymptomatic case of HAND is arguably not high, so the lower-
sensitivity test is acceptable. The prevalence of HAD was 2–4% of
HIV positive individuals in recent surveys in the US and
Switzerland [1–3], lower than the prevalence in most studies
included in this review. At this low prior probability, one might
confidently exclude the diagnosis with a negative HDS, but the
posterior probability would be less than 15% after a positive HDS.
In comparison, when used as a test for MND, a positive HDS
result would give a posterior probability of 56% in the presence of
a prior probability of 20%.
A screening test is an intervention that should be subject to
interventional research as any other, and for it to be routinely used
in clinical practice, the evidence base should address the next steps
in the clinical pathway. For example, we need to evaluate how to
investigate patients further, how to predict their outcome, and how
to modify medical therapy in the light of a positive or negative
screening test. On the tests themselves, studies are needed to
determine their repeatability, intra-subject variation, and learning
effects, and understand the causes of false positive and false
negative results (not explored in the studies reviewed). Further
studies of the HDS and IHDS should adhere to STARD
guidelines. Specific settings of interest are the use of the HDS in
an African or other resource-limited setting, or the IHDS in a
North American or European setting with high ART coverage and
relatively preserved immune function. There may be a role for
studying the scales specifically in older adults, given the growing
proportion of HIV+ individuals over the age of 50 [84] and their
greater risk of HAND [85], although their ability to distinguish
between HAND and non-HIV causes of NCI has not been
assessed. One could also model theoretical screening programmes
for neurocognitive impairment within HIV positive populations of
known prevalence.
In conclusion, in current clinical practice, interpretation of the
results of assessment with the HDS or IHDS requires an
appreciation of their limited accuracy, the lack of generalisability
of existing research, and the heterogeneity of estimates. The HDS
appears to be more accurate overall and its higher specificity
probably makes it the preferred test for detecting asymptomatic
HAND, although the IHDS may be preferred in situations where
sensitivity is most important, at the expense of loss of specificity.
Having reviewed the evidence we advise against their further use
as diagnostic tests for HAND in symptomatic patients, even in
resource-limited settings, and believe that studies reporting their
use should acknowledge their limited validity.
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